OBJECTIVE: To evaluate the short-term and long-term effects of highly active antiretroviral therapy (HAART) on tuberculosis (TB) risk compared with risk without HAART in a low TB incidence setting. DESIGN: An observational cohort study among HIV-infected persons in care at the Comprehensive Care Center (Nashville, TN) between January 1998 and December 2008. METHODS: A marginal structural model was used to estimate the effect of HAART on short-term (≤180 days) and long-term (>180 days) TB risk, with CD4⁺ lymphocyte count incorporated as a time-updated covariate. RESULTS: Of 4534 HIV-infected patients, 34 developed TB (165 per 100,000 person-years; 20,581 person-years of follow-up). Seventeen cases occurred among persons not on HAART or >30 days after HAART discontinuation (212 per 100,000 person-years; 8019 person-years of follow-up). Seventeen occurred among persons on HAART (135 per 100,000 person-years; 12,562 person-years of follow-up); 10 in the first 180 days (402 per 100,000 person-years; 2489 person-years of follow-up); and 7 after more than 180 days (69 per 100,000 person-years; 10,073 person-years of follow-up). After adjusting for the most recent CD4⁺ lymphocyte count, the risk of TB in the first 180 days of HAART exposure relative to no HAART was 0.68 (0.14-3.22, P = 0.63). CONCLUSIONS: In this low TB incidence setting, the TB rate in the first 180 days of HAART was almost twice as high as persons not on HAART. However, after adjusting for most recent CD4⁺ count, there was no significant difference in TB risk between these 2 groups. This suggests that low recent CD4⁺ lymphocyte count influences TB risk during the first 180 days of HAART.
OBJECTIVE: To evaluate the short-term and long-term effects of highly active antiretroviral therapy (HAART) on tuberculosis (TB) risk compared with risk without HAART in a low TB incidence setting. DESIGN: An observational cohort study among HIV-infectedpersons in care at the Comprehensive Care Center (Nashville, TN) between January 1998 and December 2008. METHODS: A marginal structural model was used to estimate the effect of HAART on short-term (≤180 days) and long-term (>180 days) TB risk, with CD4⁺ lymphocyte count incorporated as a time-updated covariate. RESULTS: Of 4534 HIV-infectedpatients, 34 developed TB (165 per 100,000 person-years; 20,581 person-years of follow-up). Seventeen cases occurred among persons not on HAART or >30 days after HAART discontinuation (212 per 100,000 person-years; 8019 person-years of follow-up). Seventeen occurred among persons on HAART (135 per 100,000 person-years; 12,562 person-years of follow-up); 10 in the first 180 days (402 per 100,000 person-years; 2489 person-years of follow-up); and 7 after more than 180 days (69 per 100,000 person-years; 10,073 person-years of follow-up). After adjusting for the most recent CD4⁺ lymphocyte count, the risk of TB in the first 180 days of HAART exposure relative to no HAART was 0.68 (0.14-3.22, P = 0.63). CONCLUSIONS: In this low TB incidence setting, the TB rate in the first 180 days of HAART was almost twice as high as persons not on HAART. However, after adjusting for most recent CD4⁺ count, there was no significant difference in TB risk between these 2 groups. This suggests that low recent CD4⁺ lymphocyte count influences TB risk during the first 180 days of HAART.
Authors: Maryline M B Bonnet; Loretxu L P Pinoges; Francis F V Varaine; Barbara B O Oberhauser; Daniel D O O'Brien; Yared Y K Kebede; Cathy C H Hewison; Rony R Z Zachariah; Laurent L F Ferradini Journal: AIDS Date: 2006-06-12 Impact factor: 4.177
Authors: Enrico Girardi; Caroline A Sabin; Antonella d'Arminio Monforte; Bob Hogg; Andrew N Phillips; M John Gill; Francois Dabis; Peter Reiss; Ole Kirk; Enos Bernasconi; Sophie Grabar; Amy Justice; Schlomo Staszewski; Gerd Fätkenheuer; Jonathan A C Sterne Journal: Clin Infect Dis Date: 2005-11-11 Impact factor: 9.079
Authors: A C Pettit; G Barkanic; S Stinnette; P Rebeiro; R Blackwell; S P Raffanti; B E Shepherd; T R Sterling Journal: Int J Tuberc Lung Dis Date: 2009-03 Impact factor: 2.373
Authors: Lara R Fairall; Max O Bachmann; Goedele M C Louwagie; Cloete van Vuuren; Perpetual Chikobvu; Dewald Steyn; Gillian H Staniland; Venessa Timmerman; Mpumelelo Msimanga; Chris J Seebregts; Andrew Boulle; Ralph Nhiwatiwa; Eric D Bateman; Merrick F Zwarenstein; Ronald D Chapman Journal: Arch Intern Med Date: 2008-01-14
Authors: Jonathan E Golub; Valeria Saraceni; Solange C Cavalcante; Antonio G Pacheco; Lawrence H Moulton; Bonnie S King; Anne Efron; Richard D Moore; Richard E Chaisson; Betina Durovni Journal: AIDS Date: 2007-07-11 Impact factor: 4.177
Authors: David Moore; Cheryl Liechty; Paul Ekwaru; Willy Were; Gerald Mwima; Peter Solberg; George Rutherford; Jonathan Mermin Journal: AIDS Date: 2007-03-30 Impact factor: 4.177
Authors: Graeme Meintjes; Stephen D Lawn; Fabio Scano; Gary Maartens; Martyn A French; William Worodria; Julian H Elliott; David Murdoch; Robert J Wilkinson; Catherine Seyler; Laurence John; Maarten Schim van der Loeff; Peter Reiss; Lut Lynen; Edward N Janoff; Charles Gilks; Robert Colebunders Journal: Lancet Infect Dis Date: 2008-08 Impact factor: 25.071
Authors: B Zeldow; S Kim; G McSherry; M F Cotton; P Jean-Philippe; A Violari; R Bobat; S Nachman; L M Mofenson; S A Madhi; C Mitchell Journal: Int J Tuberc Lung Dis Date: 2017-01-01 Impact factor: 2.373
Authors: Julia del Amo; Santiago Moreno; Heiner C Bucher; Hansjakob Furrer; Roger Logan; Jonathan Sterne; Santiago Pérez-Hoyos; Inma Jarrín; Andrew Phillips; Sara Lodi; Ard van Sighem; Wolf de Wolf; Caroline Sabin; Loveleen Bansi; Amy Justice; Joseph Goulet; José M Miró; Elena Ferrer; Laurence Meyer; Rémonie Seng; Giota Toulomi; Panagiotis Gargalianos; Dominique Costagliola; Sophie Abgrall; Miguel A Hernán Journal: Clin Infect Dis Date: 2012-03-28 Impact factor: 9.079